BAJAJ BROKING

Notification close image
No new Notification messages
card image
Amanta Healthcare Ltd IPO
Apply for the Amanta Healthcare Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

1726

506943

JBCHEPHARM

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

J B CHEMICALS AND PHARMA performance

Today’s low

Today’s high

₹ 1705.40 ₹ 1729.00
₹ 1724.30

52 week low

52 week high

₹ 1385.75 ₹ 1991.95
₹ 1724.30

Open Price

₹ 1706.40

Prev. Close

₹ 1706.40

Volume (Shares)

145296.00

Total traded value

₹ 2505.33

Upper Circuit

₹ 2047.60

Lower Circuit

₹ 1365.20

info

J B CHEMICALS AND PHARMA Share Price Update

As of the latest trading session, J B CHEMICALS AND PHARMA share price is currently at ₹ 1724.3, which is up by ₹ 17.90 from its previous closing. Today, the stock has fluctuated between ₹ 1705.40 and ₹ 1729.00. Over the past year, J B CHEMICALS AND PHARMA has achieved a return of -13.33 %. In the last month alone, the return has been -0.19 %. Read More...

Investment Returns

Over 1 Month -0.19% Over 3 Months 2.32% Over 6 Months 3.77% Over 1 Year -13.33%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

J B CHEMICALS AND PHARMA fundamentals


  • Market cap (Cr)

    26,977.70

  • P/E Ratio (TTM)

    39.42

  • Beta

    0.64

  • Book Value / share

    215.86

  • Return on equity

    20.84%

  • EPS (TTM)

    43.28

  • Dividend yield

    0.90%

  • Net profit/quarter (Cr)

    197.87

info icon alternate text
  • Market cap (Cr)

    26,988.70

  • P/E Ratio (TTM)

    39.42

  • Beta

    0.62

  • Book Value / share

    215.86

  • Return on equity

    20.84%

  • EPS (TTM)

    43.28

  • Dividend yield

    0.90%

  • Net profit/quarter (Cr)

    197.87

info icon alternate text

J B CHEMICALS AND PHARMA Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 1039.90
Operating Expense 788.83
Net Profit 197.87
Net Profit Margin (%) 19.02
Earnings Per Share (EPS) 12.70
EBITDA 307.02
Effective Tax Rate (%) 25.32
Particulars MAR 2025 (Values in Cr)
Revenue 901.34
Operating Expense 715.69
Net Profit 149.80
Net Profit Margin (%) 16.61
Earnings Per Share (EPS) 9.63
EBITDA 244.51
Effective Tax Rate (%) 24.78
Particulars DEC 2024 (Values in Cr)
Revenue 913.51
Operating Expense 711.14
Net Profit 156.39
Net Profit Margin (%) 17.11
Earnings Per Share (EPS) 10.06
EBITDA 252.56
Effective Tax Rate (%) 25.36
Particulars SEP 2024 (Values in Cr)
Revenue 955.76
Operating Expense 730.44
Net Profit 173.12
Net Profit Margin (%) 18.11
Earnings Per Share (EPS) 11.15
EBITDA 277.07
Effective Tax Rate (%) 26.08
Particulars JUN 2024 (Values in Cr)
Revenue 952.31
Operating Expense 723.26
Net Profit 173.23
Net Profit Margin (%) 18.19
Earnings Per Share (EPS) 11.16
EBITDA 278.54
Effective Tax Rate (%) 26.03
Particulars MAR 2025 (Values in Cr)
Revenue 3722.92
Operating Expense 2880.54
Net Profit 652.54
Net Profit Margin (%) 17.52
Earnings Per Share (EPS) 42.00
EBITDA 1052.68
Effective Tax Rate (%) 25.60
Particulars MAR 2024 (Values in Cr)
Revenue 3298.64
Operating Expense 2594.98
Net Profit 543.36
Net Profit Margin (%) 16.47
Earnings Per Share (EPS) 35.07
EBITDA 914.10
Effective Tax Rate (%) 26.40
Particulars MAR 2023 (Values in Cr)
Revenue 2884.16
Operating Expense 2365.77
Net Profit 388.89
Net Profit Margin (%) 13.48
Earnings Per Share (EPS) 50.29
EBITDA 673.33
Effective Tax Rate (%) 26.21
Particulars MAR 2022 (Values in Cr)
Revenue 2189.88
Operating Expense 1757.20
Net Profit 361.00
Net Profit Margin (%) 16.48
Earnings Per Share (EPS) 46.71
EBITDA 547.52
Effective Tax Rate (%) 23.40
Particulars MAR 2021 (Values in Cr)
Revenue 1892.00
Operating Expense 1410.18
Net Profit 447.08
Net Profit Margin (%) 23.63
Earnings Per Share (EPS) 57.85
EBITDA 668.26
Effective Tax Rate (%) 24.69
Particulars MAR 2025 (Values in Cr)
Book Value / Share 220.54
ROE % 20.75
ROCE % 26.42
Total Debt to Total Equity 0.06
EBITDA Margin 27.31
Particulars MAR 2024 (Values in Cr)
Book Value / Share 188.36
ROE % 20.45
ROCE % 24.90
Total Debt to Total Equity 0.18
EBITDA Margin 26.81
Particulars MAR 2023 (Values in Cr)
Book Value / Share 320.55
ROE % 17.77
ROCE % 22.41
Total Debt to Total Equity 0.14
EBITDA Margin 22.41
Particulars MAR 2022 (Values in Cr)
Book Value / Share 276.15
ROE % 19.58
ROCE % 25.01
Total Debt to Total Equity 0.03
EBITDA Margin 24.04
Particulars MAR 2021 (Values in Cr)
Book Value / Share 234.17
ROE % 24.75
ROCE % 32.32
Total Debt to Total Equity 0.02
EBITDA Margin 29.88
Particulars MAR 2025 (Values in Cr)
Book Value / Share 216.94
ROE % 20.84
ROCE % 26.54
Total Debt to Total Equity 0.06
EBITDA Margin 28.28
Particulars MAR 2024 (Values in Cr)
Book Value / Share 185.98
ROE % 20.39
ROCE % 24.83
Total Debt to Total Equity 0.17
EBITDA Margin 27.71
Particulars MAR 2023 (Values in Cr)
Book Value / Share 315.65
ROE % 17.11
ROCE % 21.68
Total Debt to Total Equity 0.13
EBITDA Margin 23.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 272.21
ROE % 18.46
ROCE % 23.61
Total Debt to Total Equity 0.02
EBITDA Margin 25.00
Particulars MAR 2021 (Values in Cr)
Book Value / Share 233.75
ROE % 24.61
ROCE % 32.13
Total Debt to Total Equity 0.02
EBITDA Margin 32.02
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 129.44
Total Assets 4273.77
Total Liabilities 4273.77
Total Equity 3433.31
Share Outstanding 155677208
Price to Book Ratio 7.48
Return on Assets (%) 15.43
Return on Capital (%) 19.13
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 95.53
Total Assets 3994.12
Total Liabilities 3994.12
Total Equity 2923.32
Share Outstanding 155194800
Price to Book Ratio 8.87
Return on Assets (%) 13.83
Return on Capital (%) 16.85
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 78.81
Total Assets 3553.87
Total Liabilities 3553.87
Total Equity 2480.35
Share Outstanding 77377584
Price to Book Ratio 6.24
Return on Assets (%) 11.53
Return on Capital (%) 13.53
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 58.52
Total Assets 2607.40
Total Liabilities 2607.40
Total Equity 2138.61
Share Outstanding 77282097
Price to Book Ratio 5.79
Return on Assets (%) 14.77
Return on Capital (%) 17.8
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 30.85
Total Assets 2238.11
Total Liabilities 2238.11
Total Equity 1813.42
Share Outstanding 77282097
Price to Book Ratio 5.36
Return on Assets (%) 20.01
Return on Capital (%) 24.27
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 90.56
Total Assets 4177.89
Total Liabilities 4177.89
Total Equity 3377.19
Share Outstanding 155677208
Price to Book Ratio 7.48
Return on Assets (%) 15.61
Return on Capital (%) 19.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 63.69
Total Assets 3913.63
Total Liabilities 3913.63
Total Equity 2886.26
Share Outstanding 155194800
Price to Book Ratio 8.87
Return on Assets (%) 13.88
Return on Capital (%) 16.83
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 55.76
Total Assets 3470.14
Total Liabilities 3470.14
Total Equity 2442.47
Share Outstanding 77377584
Price to Book Ratio 6.24
Return on Assets (%) 11.20
Return on Capital (%) 13.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 39.67
Total Assets 2538.06
Total Liabilities 2538.06
Total Equity 2103.66
Share Outstanding 77282097
Price to Book Ratio 5.79
Return on Assets (%) 14.22
Return on Capital (%) 16.95
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 26.42
Total Assets 2200.42
Total Liabilities 2200.42
Total Equity 1806.46
Share Outstanding 77282097
Price to Book Ratio 5.36
Return on Assets (%) 20.31
Return on Capital (%) 24.39
Particulars MAR 2025 (Values in Cr)
Net Income 887.39
Cash from Operations 1103.12
Cash from Investing -295.89
Cash from Financing -579.67
Net change in Cash 26.88
Free Cash Flow 1200.70
Particulars MAR 2024 (Values in Cr)
Net Income 751.50
Cash from Operations 933.09
Cash from Investing -403.83
Cash from Financing -385.48
Net change in Cash 11.29
Free Cash Flow 1059.96
Particulars MAR 2023 (Values in Cr)
Net Income 555.23
Cash from Operations 721.09
Cash from Investing -961.78
Cash from Financing 356.53
Net change in Cash 20.36
Free Cash Flow 793.65
Particulars MAR 2022 (Values in Cr)
Net Income 504.90
Cash from Operations 304.75
Cash from Investing 2.31
Cash from Financing -138.38
Net change in Cash 34.06
Free Cash Flow 367.62
Particulars MAR 2021 (Values in Cr)
Net Income 596.88
Cash from Operations 456.50
Cash from Investing -230.67
Cash from Financing -87.42
Net change in Cash -3.31
Free Cash Flow 504.27
Particulars MAR 2025 (Values in Cr)
Net Income 877.10
Cash from Operations 1076.87
Cash from Investing -289.92
Cash from Financing -574.26
Net change in Cash 19.84
Free Cash Flow 1172.94
Particulars MAR 2024 (Values in Cr)
Net Income 738.33
Cash from Operations 916.96
Cash from Investing -412.44
Cash from Financing -374.07
Net change in Cash 2.50
Free Cash Flow 1043.07
Particulars MAR 2023 (Values in Cr)
Net Income 527.03
Cash from Operations 717.23
Cash from Investing -955.88
Cash from Financing 343.40
Net change in Cash 16.16
Free Cash Flow 789.69
Particulars MAR 2022 (Values in Cr)
Net Income 471.29
Cash from Operations 274.22
Cash from Investing 4.17
Cash from Financing -137.85
Net change in Cash 13.42
Free Cash Flow 335.51
Particulars MAR 2021 (Values in Cr)
Net Income 593.70
Cash from Operations 475.84
Cash from Investing -230.67
Cash from Financing -86.89
Net change in Cash 17.86
Free Cash Flow 523.15
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.64 12.91 1.73 242.47 30.00 / 69.50
BLISS GVS PHARMA LTD 159.70 15.80 1.60 1684.80 105.05 / 190.65
CIPLA LTD 1578.55 23.65 4.08 127508.02 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 329.00 9.27 2.66 968.28 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.64 17.20 4.99 242.47 30.00 / 69.50
AMRUTAJAN HEALTH LTD 697.75 37.00 6.17 2017.24 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8322.70 98.39 27.00 20806.75 6222.35 / 10653.05
BLISS GVS PHARMA LTD 159.70 23.87 1.59 1684.80 105.05 / 190.65

J B CHEMICALS AND PHARMA Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1724.30 1.04 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 1723.00
  • 26 Days 1713.70
  • 10 Days 1722.90
  • 50 Days 1701.90
  • 12 Days 1721.90
  • 100 Days 1692.30
  • 20 Days 1717.10
  • 200 Days 1698.10
1707.33 PIVOT

First Support

1695.97

First Resistance

1717.77

Second Support

1685.53

Second Resistance

1729.13

Third Support

1674.17

Third Resistance

1739.57

RSI

48.23

ADX

14.82

MACD

8.15

Williams % R

-48.87

Commodity Channel Index (CCI)

-42.22

Date

2025-08-28

Week

163262.00

Same Day

133734.00

Month

131927.00

1 Year

0.65

3 Year

0.49

Over 1 Month

-0.19%

down

Over 1 Year

-13.33%

down

Over 3 Months

2.32%

down

Over 3 Years

23.85%

down

Over 6 Months

3.77%

down

Over 5 Years

33.79%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

J B CHEMICALS AND PHARMA shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
14.87%
Promoter Holdings
47.72%
FII
17.77%
DII
19.62%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Tau Investment Holdings Pte. Ltd. 7.4481519E7 (47.73%) Shareholding of Promoter and Promoter Group
Kotak Emerging Equity Scheme 6792541.0 (4.35%) Public Shareholding
Axis Mutual Fund Trustee Limited A/c Axis Mutual Fund A/c Axis Small Cap Fund 4696765.0 (3.01%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Pharma Fund 3673097.0 (2.35%) Public Shareholding
Canara Robeco Mutual Fund A/c Canara Robeco Small Cap Fund 3091206.0 (1.98%) Public Shareholding
Government Pension Fund Global 2804972.0 (1.8%) Public Shareholding
Tata Aia Life Insurance Company Ltd - Non Unit Linked Life Policy Holders Fund Participating 2032523.0 (1.3%) Public Shareholding
Franklin India Smaller Companies Fund 1733419.0 (1.11%) Public Shareholding
Smallcap World Fund, Inc 1641148.0 (1.05%) Public Shareholding

News

Left Arrow
Right Arrow

J B CHEMICALS AND PHARMA corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
30 Jul 2025 7.0 Final 30 Jul 2025 Equity shares
07 Feb 2025 8.5 Interim 08 Feb 2025 Equity shares
14 Aug 2024 6.75 Final 14 Aug 2024 Equity shares
16 Feb 2024 5.5 Interim 16 Feb 2024 Equity shares
17 Aug 2023 9.25 Final 17 Aug 2023 Equity shares
17 Feb 2023 8.5 Interim 18 Feb 2023 Equity shares
12 Aug 2022 8.0 Final 17 Aug 2022 Equity shares
23 Feb 2022 8.5 Interim 24 Feb 2022 Equity shares
01 Sep 2021 8.0 Final 02 Sep 2021 Equity shares
18 Feb 2021 8.5 Interim 22 Feb 2021 Equity shares
22 Sep 2020 1.0 Final 23 Sep 2020 Equity shares
03 Mar 2020 10.0 Interim 04 Mar 2020 Equity shares
14 Aug 2019 5.0 Final 16 Aug 2019 Equity shares
27 Aug 2018 2.0 Final 29 Aug 2018 Equity shares
11 Sep 2017 1.0 Final 13 Sep 2017 Equity shares
11 Aug 2016 0.5 Final 16 Aug 2016 Equity shares
17 Mar 2016 4.5 Interim 19 Mar 2016 Equity shares
06 Aug 2015 10.0 Special 08 Aug 2015 Equity shares
06 Aug 2015 4.0 Final 08 Aug 2015 Equity shares
04 Sep 2014 3.0 Final 06 Sep 2014 Equity shares
01 Aug 2013 3.0 Final 03 Aug 2013 Equity shares
19 Jul 2012 1.0 Final 21 Jul 2012 Equity shares
29 Aug 2011 40.0 Interim 31 Aug 2011 Equity shares
14 Jul 2011 2.0 Final 18 Jul 2011 Equity shares
15 Jul 2010 2.0 Final 19 Jul 2010 Equity shares
02 Jul 2009 1.0 Final 04 Jul 2009 Equity shares
03 Jul 2008 0.5 Final 05 Jul 2008 Equity shares
12 Jul 2007 1.5 Final 16 Jul 2007 Equity shares
13 Nov 2006 1.1 Interim 01 Jan 0001 Equity shares
Ex-Date Ex-Bonus Ratio
30 Oct 1998 05 Oct 1998 1:1
Ex-Date Old FV NEW FV Record Date
18 Sep 2023 2.0 1.0 18 Sep 2023
05 Apr 2005 10.0 2.0 12 Apr 2005
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
30 Jul 2025 7.0 Final 30 Jul 2025 Equity shares
07 Feb 2025 8.5 Interim 08 Feb 2025 Equity shares
14 Aug 2024 6.75 Final 14 Aug 2024 Equity shares
16 Feb 2024 5.5 Interim 16 Feb 2024 Equity shares
17 Aug 2023 9.25 Final 17 Aug 2023 Equity shares
17 Feb 2023 8.5 Interim 18 Feb 2023 Equity shares
12 Aug 2022 8.0 Final 17 Aug 2022 Equity shares
23 Feb 2022 8.5 Interim 24 Feb 2022 Equity shares
01 Sep 2021 8.0 Final 02 Sep 2021 Equity shares
18 Feb 2021 8.5 Interim 22 Feb 2021 Equity shares
22 Sep 2020 1.0 Final 23 Sep 2020 Equity shares
03 Mar 2020 10.0 Interim 04 Mar 2020 Equity shares
14 Aug 2019 5.0 Final 16 Aug 2019 Equity shares
27 Aug 2018 2.0 Final 29 Aug 2018 Equity shares
11 Sep 2017 1.0 Final 13 Sep 2017 Equity shares
11 Aug 2016 0.5 Final 16 Aug 2016 Equity shares
17 Mar 2016 4.5 Interim 19 Mar 2016 Equity shares
06 Aug 2015 10.0 Special 08 Aug 2015 Equity shares
06 Aug 2015 4.0 Final 08 Aug 2015 Equity shares
04 Sep 2014 3.0 Final 06 Sep 2014 Equity shares
01 Aug 2013 3.0 Final 03 Aug 2013 Equity shares
19 Jul 2012 1.0 Final 21 Jul 2012 Equity shares
29 Aug 2011 40.0 Interim 31 Aug 2011 Equity shares
14 Jul 2011 2.0 Final 18 Jul 2011 Equity shares
15 Jul 2010 2.0 Final 19 Jul 2010 Equity shares
02 Jul 2009 1.0 Final 04 Jul 2009 Equity shares
03 Jul 2008 0.5 Final 05 Jul 2008 Equity shares
12 Jul 2007 1.5 Final 16 Jul 2007 Equity shares
13 Nov 2006 1.1 Interim 01 Jan 0001 Equity shares
Ex-Date Ex-Bonus Ratio
30 Oct 1998 05 Oct 1998 1:1
Ex-Date Old FV NEW FV Record Date
18 Sep 2023 2.0 1.0 18 Sep 2023
05 Apr 2005 10.0 2.0 12 Apr 2005

J B CHEMICALS AND PHARMA Share Price

J B Chemicals & Pharmaceuticals Limited (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs). The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd.

JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into a MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from April 2000.

Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines.

In Feb. 2002 the company has achieved another break through in its major R & D Activity - Invention biologically active molecules - New Chemical Entity. In 2001-02 the company introduced 3 products Reducin XX and two in the Cholesterol reducing segment i.e., Ifistatin and Vasolip. The company has launched five new products during the year 2003-04 in the global markets to widen its product portfolio. During 2004-05, the company launched new products Cephalosporins, Moviz and its expansion Movi 3D and a nueropsychiatry product through Zephyr for the first time.

A 100% EOU manufacturing facility at Panoli for production of Gel, Ointment was commissioned during 2001-02 at a cost of Rs.21 crores and the same was financed through internal accruals. To manufacture 'DOKTOR MOM' lozenges the company is setting up two manufacturing units at Daman at a capital outlay of Rs.28 crores, which is to be financed through internal accruals. The commercial production of the Doktor Mom lozenges at its 100% Export Oriented Unit, started from 1 Sep. 2003 and tablets from 1, Jan. 2004 in Daman.Doktor Mom', the company's brand,was adjudged the Most Trusted European Brand by Reader's Digest in the cold and cough segment for the fourth consecutive year in 2003-04.

During 2004-05, the company received approval for its pharmaceutical manufacturing unit from TGA (Australia). During 2004-05, the company plants were approved by US-FDA, TGA-Australia, EDQM, MCC-South Africa, INVIMA (Colombia) and MHRA (UK).

During 2004-05, the company is setting up a new facility conforming to international standards in Panoli (Gujarat) to manufacture contrast media products by June 2006. During 2004-05, the company has planned to set up a wholly owned subsidiary in Moscow, Russia, called 'Unique Pharmaceuticals Laboratories' with the initial investment of $ 3 million.

During 2005, the company entered into two agreements, one with Pharma-a-Care Pharmaceuticals Pte. Ltd., in Australia to develop its niche products in Australian market and another with Ranbaxy Laboratories to enter in the Romanian market.

The company has subdivided the value of the share from Rs.10/- per share to Rs.2/- per share with effective from 05, April 2005.

During 2005-2006, the company has proposed to amalgamate its wholly owned subsidiary viz. lekar healthcare ltd with itself. The company has fixed April 1, 2006 as the appointed date.

During the year 2015, J.B. Chemicals & Pharmaceuticals Private Limited, Singapore, ceased to be the company's subsidiary consequent to its dissolution.

The Scheme of Amalgamation and Arrangement between Jyotindra Mody Holdings Private Limited and Ansuya Mody Securities Private Limited and Dinesh Mody Securities Private Limited and Kumud Mody Securities Private Limited and Shirish B. Mody Investments Private Limited and Bharati S. Mody Investments Private Limited (Transferor Companies) and J. B. Chemicals & Pharmaceuticals Limited (Transferee Company) and their respective shareholders under Sections 391 to 394 read with Sections 100 to 103 of the Companies Act, 1956 and Section 55 of the Companies Act, 2013 and any other applicable provisions of the Companies Act, 1956 and the Companies Act, 2013, which was approved by the Board on 15 April 2014 and members of the company at Court Convened Meeting held on 14 October 2014 and public shareholders through postal ballot and e-voting on 16 October 2014, was sanctioned by the Hon'ble Bombay High Court on 27 February 2015. The Scheme has become effective on 13 April 2015 with appointed date of 1 April 2014. Accordingly, the Transferor Companies stand merged with the company and the merger has been given effect to in the financial statements of the company for the year ended on March 31, 2015. Consequently, 4,33,42,270 equity shares of FY Rs. 2 held by the Transferor Companies in the company have been cancelled and the company has allotted 4,33,42,270 equity shares of Rs. 2 each credited as fully paid up to the shareholders of the Transferor Companies in accordance with the fair share entitlement ratio specified in the Scheme.

During the year 2016, the Company's subsidiary Unique Pharmaceutical Laboratories FZE (UPL FZE) acquired 2, 194,030 Ordinary Shares in Biotech Laboratories (Pty.) Ltd. from Afrika Biopharma Investments (Pty). Ltd. Consequent to restructuring of existing 49% shareholding in Biotech and issue of certain shares by Biotech after the aforesaid acquisition, UPL FZE now holds 95.24% voting capital of Biotech. Accordingly, Biotech has become subsidiary of the Company. Subsequently, the Company's subsidiary J.B. Healthcare Pvt. Ltd., Jersey, has been dissolved.

With a view to return surplus cash and pursuant to authority conferred under the Articles of Association of the Company, the Board approved buy-back of fully paid up equity shares of face value of Rs 2 by the Company up to 12,50,000 equity shares at a price of Rs 400 per equity share for a total consideration not exceeding Rs 5,000 lakhs (buy-back amount) excluding transaction costs, on proportionate basis through tender offer. The number of equity shares authorized for buy-back represents 1.47% of the total outstanding equity shares, while the buy-back amount represents 3.85% of the equity share capital and free reserves as at March 31, 2017. This buy-back will be implemented in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998.

The Company completed on 25 July 2017 buy-back of 1,250,000 equity shares of face of Rs. 2 at price of Rs. 400 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 83,569,975 equity shares of Rs. 2. The Company has transferred the sum of Rs. 25 lakhs from general reserves to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013.

The Company launched four new products in dermatology, amoebicide and probiotic segments during the year 2018.

The Company completed on 1st November 2018 buy-back of 3,333,333 equity shares of face value of Rs 2 at price of Rs 390 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 80,236,642 equity shares of Rs 2. The Company has transferred the sum of Rs 66.67 lakhs from general reserve to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013.

The Company launched six new products during the year 2020 across Cardiac and Gastrointestinal (GI) segments. On 2nd July, 2020, a Share Purchase Agreement was signed between founder, Mody Family members and Tau Investment Holdings Pte. Ltd., Singapore, an affiliate of global private equity firm KKR, where Tau Investment Holdings Pte. Ltd. acquired controlling stake of 41,731,363 (54%) equity shares of Rs. 2 each in the Company (JB Chemcials Pharmaceuticals Limited) from Mody Family members. Following execution of the above referred Share Purchase Agreement to acquire shares in and control over the Company, Tau Investment Holdings Pte. Ltd. and persons acting in concert made an open offer for acquiring 26% stake from public shareholders of the Company.

In FY 2021, the Company introduced newer therapeutic categories for Diabetes, Nephrology, Respiratory and Virology. It launched 10 new products across angiotensin receptor blocker, anti-diabetic, calcium channel blocker, hypotensive, anti-peptic ulcerant, anti-viral and anti-parasitic segments.

During the year 2022-23, the Company launched 17 new products in FY233 in the field of Gastro Intestinal, Gynaecology, Respiratory and Anti Diabetes. It acquired the Azmarda' brand from Novartis, a niche Paediatric portfolio from Dr Reddy and the Razel' franchise from Glenmark.

Parent organization MNC Associate
NSE symbol JBCHEPHARM
Founded 1976
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of J B Chemicals & Pharmaceuticals Ltd?

Answer Field

J B Chemicals & Pharmaceuticals Ltd share price is for NSE ₹ 1,724.30 & for BSE ₹ 1,727.00 as on Aug 29 2025 03:30 PM.

What is the Market Cap of J B Chemicals & Pharmaceuticals Ltd Share?

Answer Field

The market cap of J B Chemicals & Pharmaceuticals Ltd for NSE ₹ 26,843.42 & for BSE ₹ 26,885.46 as on Aug 29 2025 03:30 PM.

What is the 52 Week High and Low of J B Chemicals & Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of J B Chemicals & Pharmaceuticals Ltd for NSE is ₹ 1,991.95 and ₹ 1,385.75 and for BSE is ₹ 1,998.00 and ₹ 1,303.00.

What is 1 year return for J B Chemicals & Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -13.33%.

What is the P/E Ratio of J B Chemicals & Pharmaceuticals Ltd Share?

Answer Field

As on Aug 29 2025 03:30 PM the price-to-earnings (PE) ratio for J B Chemicals & Pharmaceuticals Ltd share is 39.42.

What is the PB ratio of J B Chemicals & Pharmaceuticals Ltd Share?

Answer Field

As on Aug 29 2025 03:30 PM, the price-to-book (PB) ratio for J B Chemicals & Pharmaceuticals Ltd share is 215.86.

How to Buy J B Chemicals & Pharmaceuticals Ltd Share?

Answer Field

You can trade in J B Chemicals & Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy J B Chemicals & Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy J B Chemicals & Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “J B Chemicals & Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91